Mesoporous polymeric nanoparticles for effective treatment of inflammatory diseases: an in vivo study

Abstract

Acute inflammatory diseases require suitable medicine over the existing therapeutics. In this line, the present work is focused on the development of polymeric nanomedicine for the treatment of inflammatory disorders. Herein, cell viable nanoparticles (GlyNPs) based on glycine and acryloyl chloride have been developed and proved it can be an anti-inflammatory agent without using any conventional drugs. A network pharmacology-based computational study has been executed to find out the genes and proteins responsible for the major inflammatory disease, for example, Rheumatoid Arthritis (RA). In silico docking study has been conducted to find out the targeted efficiency of the Gly NPs considering ten inflammation-specific markers such as IL-6, IL-1β, TNF-α, TLR-4, STAT-1, MAPK-8, MAPK-14, iNOS, NF-Кβ and COX-2. The results revealed that the Gly NPs could be an excellent anti-inflammatory agent similar to existing drugs. In vitro inflammation activity of these GlyNPs has been checked by developing an inflammation condition by LPS in Raw 264.7 macrophages. Then The in vitro inflammation has been treated by GlyNPs. The treatment efficiency has been checked on specified immune markers (NO level, NF-Кβ, INF-γ, IL-6, IL-10, and TNF-α) and found that the GlyNP is an excellent component in reducing the inflammation. The in vivo therapeutic response of GlyNPs, on pristane induced Rheumatoid arthritis (RA) model has been evaluated by measuring the cytokine and interferon levels responsible for the inflammation. the anti-inflammatory efficiency of GlyNPs without using any additional drugs is found excellent. Thus, GlyNPs could be paramount for the potential treatment of inflammatory diseases.